Chrysin-6-C-fucopyranoside, isolated from a local cultivar of Cyclanthera pedata, has been identified as a novel and selective PPARγ agonist, indicating its potential in managing metabolic disorders like diabetes and hyperlipidemia. Here, PPARG is linked to metabolic disease.